Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
Antonio Cuneo(Arcispedale Sant'Anna), Paolo Ghia(Vita-Salute San Raffaele University), Robin Foà(Sapienza University of Rome), George Follows(Addenbrooke's Hospital), Livio Trentin(University of Padua), Ángeles Medina Perez(Hospital Costa del Sol), Francesca Romana Mauro(Sapienza University of Rome), Kristian M. Bowles(University of East Anglia), Luca Laurenti(Sapienza University of Rome), Marta Coscia(University of Turin), Gian Matteo Rigolin, Annalisa Chiarenza(University of Catania), Lucia Farina(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Carlo Visco(University of Verona), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alfonso Piciocchi(Fondazione Gimema Onlus), Francesca Re(Azienda Ospedaliera San Gerardo), Angela Amendola, Fiorella Ilariucci(Azienda Sanitaria Unità Locale di Reggio Emilia), Toby A. Eyre(Oxford University Hospitals NHS Trust), Carol Moreno(Hospital de Sant Pau), Vittorio Meneghini(University of Verona), Stefano Molica(Azienda Ospedaliera Pugliese Ciaccio), Alfredo Rivas‐Delgado(Hospital Clínic de Barcelona), Stefania Ciolli(Azienda Ospedaliero-Universitaria Careggi), Piero Galieni, Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Anna Schuh(University of Oxford), Marcos González(Complejo Hospitalario de Salamanca), Marco Vignetti(Fondazione Gimema Onlus), Francesco Forconi(University of Leeds), Monia Marchetti(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Roberto Marasca(University of Modena and Reggio Emilia), Javier de la Serna(Hospital Universitario 12 De Octubre), Gerardo Musuraca(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Lukáš Smolej(University Hospital Hradec Králové), Atto Billio(Ospedale di Bolzano), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Ester Orlandi(University of Pavia), Ben Kennedy(University of Leeds)
Cited by 35
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k